Evidence map›Paper›PMID 33454985›Full record

ArticleThe Journal of dermatology2021

Pralatrexate for refractory mycosis fungoides in two Japanese patients.

Mika Teraishi, Tokuko Oguro, Ema Kusume, Haruka Kobashi, Hozumi Sano, Ai Fujioka, Mayuko Yamamoto, Hideki Nakajima, Shigetoshi Sano

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mika TeraishiDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.ORCID https://orcid.org/0000-0003-3445-8768
Tokuko OguroDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
Ema KusumeDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
Haruka KobashiDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
Hozumi SanoDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
Ai FujiokaDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
Mayuko YamamotoDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
Hideki NakajimaDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.ORCID https://orcid.org/0000-0001-6406-962X
Shigetoshi SanoDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.ORCID https://orcid.org/0000-0002-9812-0216
Kōchi University · JP

Funding

Mundipharma International
6 · The paper itself

Abstract

Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced-stage cutaneous T-cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily-pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.

Indexed as

Mycosis FungoidesSkin NeoplasmsAminopterinHumansJapanNeoplasm Recurrence, Local10-propargyl-10-deazaaminopterinAminopterinchemotherapycutaneous T-cell lymphomapralatrexaterefractory mycosis fungoides

Identifiers

PMID33454985
PMCPMC8248132
OpenAlexW3125846227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.